Sarah Barton

484 total citations
15 papers, 225 citations indexed

About

Sarah Barton is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Sarah Barton has authored 15 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 4 papers in Cancer Research. Recurrent topics in Sarah Barton's work include Lymphoma Diagnosis and Treatment (5 papers), Viral-associated cancers and disorders (3 papers) and HER2/EGFR in Cancer Research (3 papers). Sarah Barton is often cited by papers focused on Lymphoma Diagnosis and Treatment (5 papers), Viral-associated cancers and disorders (3 papers) and HER2/EGFR in Cancer Research (3 papers). Sarah Barton collaborates with scholars based in United Kingdom, New Zealand and United States. Sarah Barton's co-authors include Charles Swanton, David Cunningham, Naureen Starling, Andrew Wotherspoon, Eliza A. Hawkes, Thomas Ferguson, Lila Zabaglo, Suzanne C. O’Neill, Mitch Dowsett and Ian Smith and has published in prestigious journals such as Cancer Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Sarah Barton

14 papers receiving 221 citations

Peers

Sarah Barton
Alessandro D’Amuri Italy
Herlander Marques Portugal
Lina Odqvist Sweden
F. Bacci Italy
T. Pereira Portugal
Maria Karina Greece
Pedro Sánchez‐Godoy Spain
Tamara Snow United States
Blanche H. Mavromatis United States
José M. Cotrina Peru
Alessandro D’Amuri Italy
Sarah Barton
Citations per year, relative to Sarah Barton Sarah Barton (= 1×) peers Alessandro D’Amuri

Countries citing papers authored by Sarah Barton

Since Specialization
Citations

This map shows the geographic impact of Sarah Barton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Barton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Barton more than expected).

Fields of papers citing papers by Sarah Barton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Barton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Barton. The network helps show where Sarah Barton may publish in the future.

Co-authorship network of co-authors of Sarah Barton

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Barton. A scholar is included among the top collaborators of Sarah Barton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Barton. Sarah Barton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Veldhuis, Wouter B., Thomas Walter, Jens Theysohn, et al.. (2025). PRRT plus holmium‐166‐SIRT (HEPAR PLuS) versus PRRT‐only in patients with metastatic neuroendocrine tumors: A propensity‐score matched analysis. Journal of Neuroendocrinology. 37(8). e70034–e70034. 1 indexed citations
2.
Kühnl, Andrea, Clare Peckitt, Bijal Patel, et al.. (2019). R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of Hematology. 99(1). 105–112. 6 indexed citations
3.
Khan, Khurum, David Cunningham, Clare Peckitt, et al.. (2016). miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget. 7(11). 12672–12681. 35 indexed citations
4.
Barton, Sarah, Clare Peckitt, Francesco Sclafani, David Cunningham, & Ian Chau. (2015). The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. European Journal of Cancer. 51(18). 2732–2739. 5 indexed citations
5.
6.
Barton, Sarah, Eliza A. Hawkes, David Cunningham, et al.. (2014). Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐GEM‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma. European Journal Of Haematology. 94(3). 219–226. 9 indexed citations
7.
8.
Chau, Ian & Sarah Barton. (2013). ANTI-CD30 Antibody Drug Conjugate Therapy in Hodgkin Lymphoma and CD30+ Lymphoma. Annals of Oncology. 24. ix18–ix18. 1 indexed citations
9.
Hawkes, Eliza A., Sarah Barton, David Cunningham, et al.. (2013). GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Annals of Hematology. 93(5). 827–834. 7 indexed citations
10.
Barton, Sarah, Lila Zabaglo, Roger A’Hern, et al.. (2012). Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. British Journal of Cancer. 106(11). 1760–1765. 50 indexed citations
11.
Barton, Sarah, Eliza A. Hawkes, Andrew Wotherspoon, & David Cunningham. (2012). Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?. The Oncologist. 17(12). 1562–1573. 32 indexed citations
12.
Barton, Sarah, Ian E. Smith, Anna M. Kirby, et al.. (2011). The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. European Journal of Cancer. 47(14). 2099–2106. 31 indexed citations
13.
Barton, Sarah & Charles Swanton. (2011). Recent Developments in Treatment Stratification for Metastatic Breast Cancer. Drugs. 71(16). 2099–2113. 13 indexed citations
14.
Barton, Sarah, Naureen Starling, & Charles Swanton. (2010). Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets. 10(8). 799–812. 28 indexed citations
15.
Barton, Sarah, et al.. (2000). Moving forward to meet new challenges. HIV Medicine. 1(s1). 1–2. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro D’Amuri Breakdown of academic impact, for papers by Herlander Marques Breakdown of academic impact, for papers by Lina Odqvist Breakdown of academic impact, for papers by F. Bacci Breakdown of academic impact, for papers by T. Pereira Breakdown of academic impact, for papers by Maria Karina Breakdown of academic impact, for papers by Pedro Sánchez‐Godoy Breakdown of academic impact, for papers by Tamara Snow Breakdown of academic impact, for papers by Blanche H. Mavromatis Breakdown of academic impact, for papers by José M. Cotrina
Rankless by CCL
2026